These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 10441177)

  • 1. In vivo administration of intravenous immunoglobulin (IVIg) can lead to enhanced erythrocyte sequestration.
    Kessary-Shoham H; Levy Y; Shoenfeld Y; Lorber M; Gershon H
    J Autoimmun; 1999 Aug; 13(1):129-35. PubMed ID: 10441177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isoantibodies in immunoglobulin for intravenous use may cause erythrocyte sequestration.
    Shoham-Kessary H; Gershon H
    Vox Sang; 1999; 77(1):33-9. PubMed ID: 10474088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune complex-like moieties in immunoglobulin for intravenous use (i.v.Ig) bind complement and enhance phagocytosis of human erythrocytes.
    Shoham-Kessary H; Naot Y; Gershon H
    Clin Exp Immunol; 1998 Jul; 113(1):77-84. PubMed ID: 9697987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tetramolecular immune complexes are more efficient than IVIg to prevent antibody-dependent in vitro and in vivo phagocytosis of blood cells.
    Bazin R; Lemieux R; Tremblay T; St-Amour I
    Br J Haematol; 2004 Oct; 127(1):90-6. PubMed ID: 15384982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of human intravenous immunoglobulin on canine monocytes and lymphocytes.
    Reagan WJ; Scott-Moncrieff C; Christian J; Snyder P; Kelly K; Glickman L
    Am J Vet Res; 1998 Dec; 59(12):1568-74. PubMed ID: 9858408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exposure to complement-bearing immune complexes enhances the in vitro sequestration of erythrocytes from young but not elderly donors.
    Shapiro S; Pilar T; Gershon H
    Clin Exp Immunol; 1993 Feb; 91(2):301-7. PubMed ID: 8428395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune adherence of nascent hepatitis B surface antigen-antibody complexes in vivo in humans.
    Madi N; Paccaud JP; Steiger G; Schifferli JA
    Clin Exp Immunol; 1989 Nov; 78(2):201-6. PubMed ID: 12412749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythrocytes from young but not elderly donors can bind and degrade immune complex- and antibody-bound C3 in vitro.
    Shapiro S; Kohn D; Miller B; Gershon H
    Clin Exp Immunol; 1994 Jan; 95(1):181-90. PubMed ID: 8287603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clearance of anti-double-stranded DNA antibodies: the natural immune complex clearance mechanism.
    Craig ML; Bankovich AJ; McElhenny JL; Taylor RP
    Arthritis Rheum; 2000 Oct; 43(10):2265-75. PubMed ID: 11037886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haemolysis after treatment with intravenous immunoglobulin due to anti-A.
    Morgan S; Sorensen P; Vercellotti G; Zantek ND
    Transfus Med; 2011 Aug; 21(4):267-70. PubMed ID: 21605202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The binding of immune complexes to human red cells: complement requirements and fate of the RBC-bound IC after interaction with human phagocytic cells.
    Sherwood TA; Virella G
    Clin Exp Immunol; 1986 Apr; 64(1):195-204. PubMed ID: 3731526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Competition for immune complexes by red cells in human blood.
    Medof ME; Oger JJ
    J Clin Lab Immunol; 1982 Jan; 7(1):7-13. PubMed ID: 7069779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of complement-mediated immune damage by intravenous immune globulin.
    Basta M
    Clin Exp Immunol; 1996 May; 104 Suppl 1():21-5. PubMed ID: 8625538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature.
    Marie I; Maurey G; Hervé F; Hellot MF; Levesque H
    Br J Dermatol; 2006 Oct; 155(4):714-21. PubMed ID: 16965420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High dose intravenous immunoglobulin does not affect complement-bacteria interactions.
    Wagner E; Platt JL; Frank MM
    J Immunol; 1998 Feb; 160(4):1936-43. PubMed ID: 9469456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunomodulatory effects of intravenous immunoglobulins as a treatment for autoimmune diseases, cancer, and recurrent pregnancy loss.
    Sapir T; Blank M; Shoenfeld Y
    Ann N Y Acad Sci; 2005 Jun; 1051():743-78. PubMed ID: 16127014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CR1 on erythrocytes of Brazilian systemic lupus erythematosus patients: the influence of disease activity on expression and ability of this receptor to bind immune complexes opsonized with complement from normal human serum.
    Marzocchi-Machado CM; Alves CM; Azzolini AE; Polizello AC; Carvalho IF; Lucisano-Valim YM
    J Autoimmun; 2005 Dec; 25(4):289-97. PubMed ID: 16289666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid.
    Gürcan HM; Ahmed AR
    Ann Pharmacother; 2007 Oct; 41(10):1604-10. PubMed ID: 17785614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune complex alterations occur on the human red blood cell membrane.
    Medof ME; Prince GM
    Immunology; 1983 Sep; 50(1):11-8. PubMed ID: 6224741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune complex binding by immunocamouflaged [poly(ethylene glycol)-grafted] erythrocytes.
    Bradley AJ; Scott MD
    Am J Hematol; 2007 Nov; 82(11):970-5. PubMed ID: 17654505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.